Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Taligen Therapeutics

2004 FOUNDED
M&A STATUS
M&A LATEST DEAL TYPE
$111M LATEST DEAL AMOUNT
Description

Provider of development stage biotechnology services for the treatment of inflammatory diseases. The company is developing therapies that regulate the complement system to treat inflammatory and immune diseases.

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Acquirer
Primary Office
  • Cambridge, MA
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Taligen Therapeutics’s full profile, request a free trial.

Taligen Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 31-Jan-2011 $111M 000.00 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 23-Aug-2010 0000 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 01-Aug-2006 $3.7M $3.7M Completed Product Development
To view this company’s complete deal history including valuation and funding, request access »

Taligen Therapeutics Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Alta Partners Venture Capital Minority 000 0000 000000 0
Clarus Ventures Venture Capital Minority 000 0000 000000 0
High Country Venture Venture Capital Minority 000 0000 000000 0
Sanderling Ventures Venture Capital Minority 000 0000 000000 0
University License Equity Holding Corporation Minority 000 0000 000000 0